NeRRe Therapeutics is a UK based clinical-stage company developing a unique portfolio of neurokinin (NK) receptor antagonists for the treatment of common debilitating conditions caused by neuronal hypersensitivity.

Find Out More

Our Belief

We believe that the NK receptor system presents one of the most exciting yet clinically under-exploited neuropeptide target classes, which has huge potential for a broad range of indications to provide truly innovative treatments to meet medical unmet needs.

Our Focus

NeRRe’s ambition is to unlock the significant potential of its full pipeline in particular to progress the two late stage NK antagonists to the next stage of development. The NeRRe focus is on developing novel treatments to address common, chronic and debilitating conditions that affect millions of people around the world on a daily basis.


In keeping with our ambition for this target class we are keen to explore opportunities to further develop the other high-quality NK receptor antagonists in our pipeline to enable the full therapeutic promise of this neuropeptide receptor system to be realised.

Find Out More

Latest News

Jan 17

NeRRe Therapeutics raises £23 million in oversubscribed Series B financing round

New funds to advance unique neurokinin receptor antagonist pipeline towards late-stage clinical development in common, chronic and debilitating respiratory and women’s health conditions.

read more
Sep 15

Dr Mary Kerr to join NeRRe Therapeutics as CEO

NeRRe Therapeutics Ltd, a clinical stage company developing a portfolio of neurokinin (NK) receptor antagonists, is pleased to announce that Dr Mary Kerr is joining the company as CEO at the beginning of October

read more

Get In Touch

For general, media or partnership enquiries, get in touch using the form below:

Your Name (required)

Your Email (required)

Your Message